Clinical and Economic Impact of Formulary Conversion From Inhaled Flolan to Inhaled Veletri for Refractory Hypoxemia in Critically Ill Patients

Annals of Pharmacotherapy

Volumn 50, Issue 2, 2016, Pages 106-112

  Torbic, Heather ^a   Szumita, Paul M ^b   Anger, Kevin E ^b   Nuccio, Paul ^b   Lagambina, Susan ^b   Weinhouse, Gerald ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

critical care; pharmacoeconomics; prostaglandins; respiratory failure; vasodilators

Indexed keywords

NITRIC OXIDE; PROSTACYCLIN; PYRIDINE DERIVATIVE; TETRAZOLE DERIVATIVE; TEZOSENTAN; VASODILATOR AGENT;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; APACHE; ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; COHORT ANALYSIS; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INDEX; HEART OUTPUT; HUMAN; HYPOTENSION; HYPOXEMIA; INTENSIVE CARE UNIT; LENGTH OF STAY; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OXYGENATION; PRIORITY JOURNAL; REFRACTORY HYPOXEMIA; RETROSPECTIVE STUDY; TACHYCARDIA; TREATMENT DURATION; TREATMENT OUTCOME; AGED; ANOXIA; CRITICAL ILLNESS; RESPIRATORY DISTRESS SYNDROME, ADULT; RESPIRATORY INSUFFICIENCY; TIME FACTOR;

ADULT; AGED; ANOXIA; CRITICAL ILLNESS; EPOPROSTENOL; FEMALE; HUMANS; INTENSIVE CARE UNITS; LENGTH OF STAY; MALE; MIDDLE AGED; PYRIDINES; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDIES; TETRAZOLES; TIME FACTORS; VASODILATOR AGENTS;

EID: 84954321124     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028015621308     Document Type: Article

References (26)

1. H.TorbicP.M.SzumitaK.E.Anger. Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients. J Crit Care. 2013;28:844-848.
2. D.WalmrathT.SchneiderR.Schermuly. Direct comparison of inhaled nitric oxide and aerosolized prostacyclin in acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996;153:991-996.
3. G.D.RoccaC.CocciaL.Pompei. Hemodynamic and oxygenation changes of combined therapy with inhaled nitric oxide and inhaled prostacyclin. J Cardiothorac Vasc Anesth. 2001;15:224-227.
4. T.A.KhanG.SchnickelD.Ross. A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients. J Thorac Cardiovasc Surg. 2009;138:1417-1424.
5. M.Gromberg-MaitlandH.Olschewski. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J. 2008;31:891-901.
6. A.L.DzierbaE.E.AbelM.S.BuckleyI.Lat. A review of inhaled nitric oxide and aerosolized epoprostenol in acute lung injury or acute respiratory distress syndrome. Pharmacotherapy. 2014;34:279-290.
7. M.S.BuckleyJ.P.Feldman. Inhaled epoprostenol for the treatment of pulmonary arterial hypertension in critically ill adults. Pharmacotherapy. 2010;30:728-740.
8. Flolan (epoprostenol sodium) for injection [prescribing information].Research Triangle Park, NC: GlaxoSmith Kline; 2011.
9. Veletri (epoprostenol sodium) for injection [prescribing information].South San Francisco, CA: Actelion Pharmaceuticals; 2011.
10. K.S.McCoyA.L.QuittnerC.M.Oermann. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008;178:921-928.
11. K.ZeitlerB.SalvasV.StevensJ.Brown. Aztreonam lysine for inhalation: new formulation of an old antibiotic. Am J Health Syst Pharm. 2012;69:107-115.
12. Azactam® (aztreonam) for injection [prescribing information].Princeton, NJ: Bristol-Myers Squibb Company; 2013.
13. Cayston® (aztreonam) for inhalation [prescribing information].Mississauga, ON, Canada: Gilead Sciences, Inc; 2012.
14. H.J.DietzschB.GottschalkK.HeyneW.LeupoldP.Wunderlich. Cystic fibrosis: comparison of two mucolytic drugs for inhalation treatment (acetylcysteine and arginine hydrochloride). Pediatrics. 1975;55:96-100.
15. R.RossaintK.J.FalkeF.Lopez. Inhaled nitric oxide for the adult respiratory distress syndrome. N Engl J Med. 1993;328:399-405.
16. B.ZwisslerG.KemmingO.Habler. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154(6, pt 1):1671-1677.
17. A.HaraldssonN.Kieler-JensenU.Nathorst-Westfelt. Comparison of inhaled nitric oxide and inhaled aerosolized prostacyclin in the evaluation of heart transplant candidates with elevated pulmonary vascular resistance. Chest. 1998;114:780-786.
18. P.V.Van HeerdenD.BlytheS.A.Webb. Inhaled aerosolized prostacyclin and nitric oxide as selective pulmonary vasodilators in ARDS: a pilot study. Anaesth Intensive Care. 1996;24:564-568.
19. A.AfshariJ.BrokA.M.Moller. Inhaled nitric oxide for acute respiratory distress syndrome and acute lung injury in adults and children: a systematic review with meta-analysis and trial sequential analysis. Anesth Analg. 2011;112:1411-1421.
20. C.J.De WetD.G.AffleckE.Jacobsohn. Inhaled prostacyclin is safe, effective, and affordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg. 2004;127:1058-1067.
21. S.M.LowsonA.DoctorB.K.Walsh. Inhaled prostacyclin for the treatment of pulmonary hypertension after cardiac surgery. Crit Care Med. 2002;30:2762-2764.
22. S.M.FiserJ.T.CopeI.L.Kron. Aerosolized prostacyclin (epoprostenol) as an alternative to inhaled nitric oxide for patients with reperfusion injury after lung transplantation. J Thorac Cardiovasc Surg. 2001;121:981-982.
23. J.MeyerG.TheilmeierH.Van Aken. Inhaled prostaglandin E1 for treatment of acute lung injury in severe multiple organ failure. Anesth Analg. 1998;86:753-758.
24. J.M.CamamoR.H.McCoyB.L.Erstad. Retrospective evaluation of inhaled prostaglandins in patients with acute respiratory distress syndrome. Pharmacotherapy. 2005;25:184-190.
25. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342:1301-1308.
26. M.ZambonJ.L.Vincent. Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest. 2008;133:20-27.